GI Stool Testing Market Is Projected to Expand At A CAGR Of XX% Between 2023 And 2031. Stools tests are performed to diagnose GI tract disorders and aid in the detection of parasites infection, bleeding obstruction, and inflammation. Stools tests can further be utilized for the diagnosis of colorectal cancer or the presence of pathogens such as Rotavirus, C. difficile, H. pylori among others in the GI tract. Laboratory tests used for stool testing are either microbial particle-based or antibody-based, which include chemiluminescence immunoassays (CLIA), immunoassays, and molecular diagnostic testing.
Increased incidence of C. difficile infections and other gastrointestinal diseases increases the demand for stool tests, thereby driving the global GI stool testing market. According to the Centers for Disease Control and Prevention, in 2014, an estimated of 14.8 million adults were diagnosed with ulcers and other digestive disorders in the United States. Furthermore, in 2017, 135,430 new cases of colorectal cancer were diagnosed in the country, raising the demand for GI stool testing. However, the challenge of accurate testing restrains the market.
The global GI stool testing market is segmented based on product type, application, test type, end-user, and geography. Among product types, the reagents segment dominated the global market in 2017 with over 60% of the market share. Among applications, the GI tract infections segment led the global market in 2023 owing to high prevalent cases and increased awareness regarding gastrointestinal disorders. Based on end-users, hospitals will continue to dominate the market owing to the high procedural load of the tests.
North America is anticipated to lead the global market owing to the high awareness of gastrointestinal disorders and the availability of evolved healthcare infrastructure. Manufacturers are focusing on emerging markets including the Asia Pacific and Latin America due to the presence of potential opportunities.
Key Players Identified in GI Stool Testing Market include:
BioMrieux Inc, Meridian Bioscience Inc, DiaSorin S.p.A., Beckman Coulter Inc., Alere Inc., Bio Rad Laboratories, Cenogenics Corporation, Siemens Healthcare, Quest Diagnostics Incorporated, Abbott Laboratories and Others.
Historical & Forecast Period
This study report represents analysis of each segment from 2022 to 2032 considering 2023 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2024 to 2032.
The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.
Research Methodology
The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of GI Stool Testing market are as follows:
Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.
ATTRIBUTE | DETAILS |
---|---|
Research Period | 2022-2032 |
Base Year | 2023 |
Forecast Period | 2024-2032 |
Historical Year | 2022 |
Unit | USD Million |
Segmentation | |
Product
| |
Application
| |
Test Type
| |
End-user
| |
Region Segment (2022-2032; US$ Million)
|
Key questions answered in this report